277 related articles for article (PubMed ID: 33373044)
1. Evolution of adrenoleukodystrophy model systems.
Montoro R; Heine VM; Kemp S; Engelen M
J Inherit Metab Dis; 2021 May; 44(3):544-553. PubMed ID: 33373044
[TBL] [Abstract][Full Text] [Related]
2. X-linked adrenoleukodystrophy and primary adrenal insufficiency.
Cappa M; Todisco T; Bizzarri C
Front Endocrinol (Lausanne); 2023; 14():1309053. PubMed ID: 38034003
[TBL] [Abstract][Full Text] [Related]
3. [X-linked adrenoleukodystrophy].
Aubourg P
Ann Endocrinol (Paris); 2007 Dec; 68(6):403-11. PubMed ID: 17532287
[TBL] [Abstract][Full Text] [Related]
4. Adrenoleukodystrophy - neuroendocrine pathogenesis and redefinition of natural history.
Kemp S; Huffnagel IC; Linthorst GE; Wanders RJ; Engelen M
Nat Rev Endocrinol; 2016 Oct; 12(10):606-15. PubMed ID: 27312864
[TBL] [Abstract][Full Text] [Related]
5. Structure and Function of the
Mallack EJ; Gao K; Engelen M; Kemp S
Cells; 2022 Jan; 11(2):. PubMed ID: 35053399
[TBL] [Abstract][Full Text] [Related]
6. Novel
Cho YK; Lee SY; Kim SW
Endocrinol Metab (Seoul); 2020 Mar; 35(1):188-191. PubMed ID: 32207279
[TBL] [Abstract][Full Text] [Related]
7. ABC subfamily D proteins and very long chain fatty acid metabolism as novel targets in adrenoleukodystrophy.
Morita M; Shimozawa N; Kashiwayama Y; Suzuki Y; Imanaka T
Curr Drug Targets; 2011 May; 12(5):694-706. PubMed ID: 21039332
[TBL] [Abstract][Full Text] [Related]
8. X-linked adrenoleukodystrophy: pathogenesis and treatment.
Engelen M; Kemp S; Poll-The BT
Curr Neurol Neurosci Rep; 2014 Oct; 14(10):486. PubMed ID: 25115486
[TBL] [Abstract][Full Text] [Related]
9. ABCD1 and X-linked adrenoleukodystrophy: A disease with a markedly variable phenotype showing conserved neurobiology in animal models.
Manor J; Chung H; Bhagwat PK; Wangler MF
J Neurosci Res; 2021 Dec; 99(12):3170-3181. PubMed ID: 34716609
[TBL] [Abstract][Full Text] [Related]
10. Two Single Nucleotide Deletions in the
Dohr KA; Tokic S; Gastager-Ehgartner M; Stojakovic T; Dumic M; Plecko B; Dumic KK
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36983033
[TBL] [Abstract][Full Text] [Related]
11. A report on state-wide implementation of newborn screening for X-linked Adrenoleukodystrophy.
Wiens K; Berry SA; Choi H; Gaviglio A; Gupta A; Hietala A; Kenney-Jung D; Lund T; Miller W; Pierpont EI; Raymond G; Winslow H; Zierhut HA; Orchard PJ
Am J Med Genet A; 2019 Jul; 179(7):1205-1213. PubMed ID: 31074578
[TBL] [Abstract][Full Text] [Related]
12. The clinical spectrum of X-linked adrenoleukodystrophy: from Addison's-only in men to middle-age neurologic manifestations in women.
Fadiga L; Melo M; Saraiva J; Paiva I
Hormones (Athens); 2022 Mar; 21(1):33-40. PubMed ID: 34652632
[TBL] [Abstract][Full Text] [Related]
13. Spastic paraplegia as the predominant phenotype in a cohort of Chinese patients with adrenoleukodystrophy.
Luo WJ; Wei Q; Dong HL; Yan YT; Chen MJ; Li HF
Mol Genet Genomic Med; 2020 Jan; 8(1):e1065. PubMed ID: 31777199
[TBL] [Abstract][Full Text] [Related]
14. [Adrenoleukodystrophy: molecular pathogenesis and development of therapeutic agents].
Morita M
Yakugaku Zasshi; 2007 Jul; 127(7):1059-64. PubMed ID: 17603264
[TBL] [Abstract][Full Text] [Related]
15. Management of adrenoleukodystrophy: From pre-clinical studies to the development of new therapies.
Ma CY; Li C; Zhou X; Zhang Z; Jiang H; Liu H; Chen HJ; Tse HF; Liao C; Lian Q
Biomed Pharmacother; 2021 Nov; 143():112214. PubMed ID: 34560537
[TBL] [Abstract][Full Text] [Related]
16. CYP4F2 affects phenotypic outcome in adrenoleukodystrophy by modulating the clearance of very long-chain fatty acids.
van Engen CE; Ofman R; Dijkstra IM; van Goethem TJ; Verheij E; Varin J; Vidaud M; Wanders RJ; Aubourg P; Kemp S; Barbier M
Biochim Biophys Acta; 2016 Oct; 1862(10):1861-70. PubMed ID: 27425035
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic potential of deuterium-stabilized (R)-pioglitazone-PXL065-for X-linked adrenoleukodystrophy.
Monternier PA; Singh J; Parasar P; Theurey P; DeWitt S; Jacques V; Klett E; Kaur N; Nagaraja TN; Moller DE; Hallakou-Bozec S
J Inherit Metab Dis; 2022 Jul; 45(4):832-847. PubMed ID: 35510808
[TBL] [Abstract][Full Text] [Related]
18. Biochemical aspects of X-linked adrenoleukodystrophy.
Kemp S; Wanders R
Brain Pathol; 2010 Jul; 20(4):831-7. PubMed ID: 20626744
[TBL] [Abstract][Full Text] [Related]
19. Functional genomic analysis unravels a metabolic-inflammatory interplay in adrenoleukodystrophy.
Schlüter A; Espinosa L; Fourcade S; Galino J; López E; Ilieva E; Morató L; Asheuer M; Cook T; McLaren A; Reid J; Kelly F; Bates S; Aubourg P; Galea E; Pujol A
Hum Mol Genet; 2012 Mar; 21(5):1062-77. PubMed ID: 22095690
[TBL] [Abstract][Full Text] [Related]
20. Molecular Biomarkers for Adrenoleukodystrophy: An Unmet Need.
Honey MIJ; Jaspers YRJ; Engelen M; Kemp S; Huffnagel IC
Cells; 2021 Dec; 10(12):. PubMed ID: 34943935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
